|
CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC's CAP technology
CEVEC an CSL Limited announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema...
|
|
WuXi STA Changzhou Site Passes First U.S. FDA Inspection
STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection for two APIs from the U.S. FDA with no Form 483s issued.
|
|